Serum beta-2 microglobulin in malignant lymphomas: An old but powerful prognostic factor

Blood Research

Volumn 49, Issue 3, 2014, Pages 148-153

  Yoo, Changhoon ^a   Yoon, Dok Hyun ^a   Suh, Cheolwon ^a  

^a University of Ulsan College of Medicine   (South Korea)

Author keywords

Beta 2 microglobulin; Lymphoma; Prognostic factor

Indexed keywords

BETA 2 MICROGLOBULIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; PREDNISOLONE; RITUXIMAB; TOSITUMOMAB; VINCRISTINE;

ARTICLE; CANCER PROGNOSIS; FOLLICULAR LYMPHOMA; HISTOCOMPATIBILITY COMPLEX; HODGKIN DISEASE; HUMAN; LARGE CELL LYMPHOMA; LYMPHOMA; MANTLE CELL LYMPHOMA; MARGINAL ZONE LYMPHOMA; MEDICAL DECISION MAKING; MULTIPLE MYELOMA; NONHODGKIN LYMPHOMA; PROTEIN BLOOD LEVEL;

EID: 84911425092     PISSN: 2287979X     EISSN: 22880011     Source Type: Journal    
DOI: 10.5045/br.2014.49.3.148     Document Type: Article

References (33)

1. Peterson PA, Cunningham BA, Berggard I, Edelman GM. ß2-microglobulin-a free immunoglobulin domain. Proc Natl Acad Sci U S A 1972;69:1697-701.
2. Grey HM, Kubo RT, Colon SM, et al. The small subunit of HL-A antigens is beta 2-microglobulin. J Exp Med 1973;138:1608-12.
3. Shi C, Zhu Y, Su Y, Chung LW, Cheng T. Beta2-microglobulin: emerging as a promising cancer therapeutic target. Drug Discov Today 2009;14:25-30.
4. Munshi NC, Anderson KC, Bergsagel PL, et al. Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2. Blood 2011;117:4696-700.
5. Federico M, Bellei M, Marcheselli L, et al. Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project. J Clin Oncol 2009;27:4555- 62.
6. Vassilakopoulos TP, Nadali G, Angelopoulou MK, et al. The prognostic significance of beta(2)-microglobulin in patients with Hodgkin's lymphoma. Haematologica 2002;87:701-8.
7. Yoo C, Yoon DH, Jo JC, et al. Prognostic impact of beta-2 microglobulin in patients with extranodal natural killer/T cell lymphoma. Ann Hematol 2014;93:995-1000.
8. Federico M, Guglielmi C, Luminari S, et al. Prognostic relevance of serum beta2 microglobulin in patients with follicular lymphoma treated with anthracycline-containing regimens. A GISL study. Haematologica 2007;92:1482-8.
9. Josson S, Nomura T, Lin JT, et al. ß2-microglobulin induces epithelial to mesenchymal transition and confers cancer lethality and bone metastasis in human cancer cells. Cancer Res 2011;71: 2600-10.
10. Chen CH, Su CY, Chien CY, et al. Overexpression of beta2-microglobulin is associated with poor survival in patients with oral cavity squamous cell carcinoma and contributes to oral cancer cell migration and invasion. Br J Cancer 2008;99:1453-61.
11. Hagberg H, Killander A, Simonsson B. Serum beta 2-microglobulin in malignant lymphoma. Cancer 1983;51:2220-5.
12. Anderson H, Scarffe JH, Swindell R, Crowther D. Serum beta 2-microglobulin in patients with non-Hodgkin's lymphoma. Eur J Cancer Clin Oncol 1983;19:327-31.
13. Hahn JS, Lee S, Chong SY, Min YH, Ko YW. Eight-year experience of malignant lymphoma-survival and prognostic factors. Yonsei Med J 1997;38:270-84.
14. Lopez-Guillermo A, Colomo L, Jimenez M, et al. Diffuse large B-cell lymphoma: clinical and biological characterization and outcome according to the nodal or extranodal primary origin. J Clin Oncol 2005;23:2797-804.
15. Johnson PW, Whelan J, Longhurst S, et al. Beta-2 microglobulin: a prognostic factor in diffuse aggressive non-Hodgkin's lymphomas. Br J Cancer 1993;67:792-7.
16. Alici S, Bavbek SE, Kaytan E, Eralp Y, Onat H. Prognostic factors in localized aggressive non-Hodgkin's lymphoma. Am J Clin Oncol 2003;26:1-5.
17. Romaguera JE, Fayad L, Rodriguez MA, et al. High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine. J Clin Oncol 2005;23:7013-23.
18. Litam P, Swan F, Cabanillas F, et al. Prognostic value of serum beta-2 microglobulin in low-grade lymphoma. Ann Intern Med 1991;114:855-60.
19. Solal-Celigny P, Roy P, Colombat P, et al. Follicular lymphoma international prognostic index. Blood 2004;104:1258-65.
20. Press OW, Unger JM, Rimsza LM, et al. A comparative analysis of prognostic factor models for follicular lymphoma based on a phase III trial of CHOP-rituximab versus CHOP + 131iodinetositumomab. Clin Cancer Res 2013;19:6624-32.
21. Thieblemont C, Berger F, Dumontet C, et al. Mucosa-associated lymphoid tissue lymphoma is a disseminated disease in one third of 158 patients analyzed. Blood 2000;95:802-6.
22. Zucca E, Conconi A, Pedrinis E, et al. Nongastric marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue. Blood 2003;101:2489-95.
23. Arcaini L, Burcheri S, Rossi A, et al. Nongastric marginal-zone B-cell MALT lymphoma: prognostic value of disease dissemination. Oncologist 2006;11:285-91.
24. Yoo C, Yoon DH, Yoon S, et al. Prognostic impact of ß2- microglobulin in patients with non-gastric mucosa-associated lymphoid tissue lymphoma. Leuk Lymphoma 2014;17:1-6.
25. Oh SY, Kwon HC, Kim WS, et al. Nongastric marginal zone B-cell lymphoma: a prognostic model from a retrospective multicenter study. Cancer Lett 2007;258:90-7.
26. Li ZM, Zhu YJ, Sun J, et al. Serum beta2-microglobin is a predictor of prognosis in patients with upper aerodigestive tract NK/T-cell lymphoma. Ann Hematol 2012;91:1265-70.
27. Lee J, Suh C, Park YH, et al. Extranodal natural killer T-cell lymphoma, nasal-type: a prognostic model from a retrospective multicenter study. J Clin Oncol 2006;24:612-8.
28. Rodriguez J, Conde E, Gutierrez A, et al. The adjusted International Prognostic Index and beta-2-microglobulin predict the outcome after autologous stem cell transplantation in relapsing/refractory peripheral T-cell lymphoma. Haematologica 2007;92:1067-74.
29. Dimopoulos MA, Cabanillas F, Lee JJ, et al. Prognostic role of serum beta 2-microglobulin in Hodgkin's disease. J Clin Oncol 1993;11:1108-11.
30. Chronowski GM, Wilder RB, Tucker SL, et al. An elevated serum beta-2-microglobulin level is an adverse prognostic factor for overall survival in patients with early-stage Hodgkin disease. Cancer 2002;95:2534-8.
31. Itoh K, Kinoshita T, Watanabe T, et al. Prognostic analysis and a new risk model for Hodgkin lymphoma in Japan. Int J Hematol 2010;91:446-55.
32. Yang J, Zhang X, Wang J, et al. Anti beta2-microglobulin monoclonal antibodies induce apoptosis in myeloma cells by recruiting MHC class I to and excluding growth and survival cytokine receptors from lipid rafts. Blood 2007;110:3028-35.
33. Yang J, Cao Y, Hong S, et al. Human-like mouse models for testing the efficacy and safety of anti-beta2-microglobulin monoclonal antibodies to treat myeloma. Clin Cancer Res 2009;15:951-9.